We are developing first-in-class drugs that
* Target a gene mutation found in over 80% of colorectal cancer (CRC) patients &
* Remyelinate nerve cells in multiple sclerosis (MS)

We’ve already seen unprecedented activity in animal colorectal cancer models leveraging synthetic lethality, without toxicity. And we have a clear development strategy to reach human proof of concept in Colorectal Cancer in 2023 and human proof of concept in Demyelinating Diseases in 2024 with our EBP Inhibitor drugs.

0

people a year die from
colorectal cancer worldwide.

#2

Colorectal cancer is the 2nd leading cause of cancer deaths worldwide.

$10B

estimated worldwide market.

Globocan 2020 cancer statistics

Despite newer therapies such as EGFR, VEGF inhibitors & immuno-oncology agents, CRC remains a deadly disease with ~50,000 deaths annually in the US alone. With the need for newer treatment options in this patient population, the worldwide market opportunity is ~$10 Billion.

Our Drug Platforms:
TASIN in Oncology & Neurology

TASIN in Colorectal Cancer is lethal for mutated APC cancer cells, while having virtually no effect on normal cells.

TASIN in multiple sclerosis (MS) directly binds and inhibits a target gaining much interest in the Pharma industry, emopamil binding protein (EBP), which results in the formation of myelin around nerve cells.

TASIN has shown to be highly potent, resulting in significant inhibition of CRC tumor growth, with no apparent toxicity to normal cells.

We have fantastic binding data between TASIN and EBP which has been confirmed using multiple approaches including use of CRISPR technology.

Learn More
"We expect TASIN for CRC to be in the clinic in 2023, with human proof of concept in 2023-2024. There are also some very interesting opportunities for TASIN in demyelinating diseases — such as multiple sclerosis (MS). We have seen biological effects of our TASINs in a gold standard MS animal and are planning to identify lead candidate TASIN molecules to enable IND-enabling studies.
Interestingly, other Pharma Co.'s are now pursuing EBP as a drugable target in both cancer and MS indications. We’re currently seeking investors to reach key value inflection points."

Neil Thapar

CEO & Chief Scientific Officer